Your browser doesn't support javascript.
loading
MRI-Based Tumor Necrosis Depiction in Pancreatic Ductal Adenocarcinoma: Can It Predict Tumor Aggressiveness?
Anderson, Mark A; Knipp, David E; Noda, Yoshifumi; Kamran, Sophia C; Baliyan, Vinit; Kordbacheh, Hamed; Hong, Theodore S; Kambadakone, Avinash.
Afiliação
  • Anderson MA; Department of Radiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA .
  • Knipp DE; Department of Radiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA .
  • Noda Y; Department of Radiology, Gifu University, 1-1-1 Yanagido Street, Gifu City 501-1194, Japan.
  • Kamran SC; Department of Radiation Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
  • Baliyan V; Department of Radiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA .
  • Kordbacheh H; Department of Radiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA .
  • Hong TS; Department of Radiation Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
  • Kambadakone A; Department of Radiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA .
Cancers (Basel) ; 15(8)2023 Apr 15.
Article em En | MEDLINE | ID: mdl-37190241
The purpose of this study was to investigate whether tumor necrosis depicted on contrast-enhanced abdominal MRI can predict tumor aggressiveness in pancreatic ductal adenocarcinoma (PDAC). In this retrospective analysis, we included 71 patients with pathology-proven PDAC who underwent contrast-enhanced MRI from 2006 to 2020. Assessment for the presence/absence of imaging detected necrosis was performed on T2-weighted and contrast-enhanced T1-weighted images. Primary tumor characteristics, regional lymphadenopathy, metastases, stage, and overall survival were analyzed. Fisher's exact and Mann-Whitney U tests were used for statistical analysis. Of the 72 primary tumors, necrosis was identified on MRI in 58.3% (42/72). Necrotic PDACs were larger (44.6 vs. 34.5 mm, p = 0.0016), had higher rates of regional lymphadenopathy (69.0% vs. 26.7%, p = 0.0007), and more frequent metastases (78.6% vs. 40.0%, p = 0.0010) than those without MRI-evident necrosis. A non-statistically significant reduction in median overall survival was observed in patients with versus without MRI-evident necrosis (15.8 vs. 38.0 months, p = 0.23). PDAC tumor necrosis depicted on MRI was associated with larger tumors and higher frequency of regional lymphadenopathy and metastases.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article